Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
Open-label, long-term safety study of ARQ-154 foam 0.3% in subjects with seborrheic
dermatitis involving up to 20% total Body Surface Area (BSA). Study medication will be
applied by the qualifying subjects topically once daily for 52 weeks. Cohort 1 subjects are
rollover subjects from a prior ARQ-154 trial. Cohort 2 include treatment naive subjects.
Periodic clinic visits will include assessments for clinical safety, application site
reactions, and disease improvement or progression.